We Don't Need More Reasons to Reject Heritable Genome Modification
By Katie Hasson,
The Hill
| 06. 10. 2019
Late last year, scientist He Jiankui announced the birth of the world’s first genetically modified babies. He deployed a technology known as CRISPR to alter the genomes of two embryos that he used to initiate a pregnancy; their mother carried the pregnancy until the two girls, publicly called Lulu and Nana, were delivered prematurely by C-section.
The response of scientists, bioethicists, and the public was immediate and overwhelmingly negative. He’s reckless actions violated Chinese regulations, crossed a bright line that dozens of countries have written into their laws, flouted nearly every rule of medical ethics, and exposed two girls to grave and unknowable risks.
This week, a study emerged highlighting the dangers of what He did, especially based on our current level of understanding. He attempted to disable a gene called CCR5 by producing a variant that has been shown to confer resistance to HIV. But the new study suggests that having non-working copies of CCR5 actually has an overall negative effect on health, specifically a 21 percent increase in mortality before age 76.
These findings...
Related Articles
By Sarojini Nadimpally and Gargi Mishra, The Wire | 12.15.2024
In-vitro fertilisation (IVF) as assisted reproductive technology (ART) has been in vogue for quite a few decades now. While IVF has been hailed as a significant scientific advancement, with many advantages, here are some limitations which bear keeping in mind...
Image by Mohamed Hassan from Pixabay
It is hard to make predictions, especially about the future, as Yogi Berra, Niels Bohr, and other luminaries have remarked. But there are already signs that the incoming Trump administration may have some difficulty establishing consistent policies about controversial issues concerning human reproduction.
On the one hand, consider “the conservative blueprint for a second Trump administration.”
The notorious Project 2025’s Mandate for Leadership seeks to delete terms such as “reproductive rights” from “every federal...
By Susan Dominus, The New York Times | 11.30.2024
In the days after Daphna Cardinale delivered her second child, she experienced a rare sense of calm and wonder. The feeling was a relief after so much worrying: She and her husband, Alexander, had tried for three years to conceive...
By Christy Santhosh, Reuters | 11.27.2024
Nov 27 (Reuters) - The U.S. Food and Drug Administration is weighing the need for regulatory action on bluebird bio's (BLUE.O), opens new tab gene therapy for a rare neurological disorder, it said on Wednesday, as the agency probes additional...